CD274 and melanoma: In another study, researchers engineered Golgi apparatus-PDL1 exosome hybrid membrane-coated nanoparticles to block the production of PD-L1-bearing TEXs by targeting the Golgi apparatus in melanoma cells, as patients resistant to anti-PDL1 medication have elevated levels of TEXs containing PD-L1 [161, 162].